drugset / Trial / NCT02046200

Development of Ivermectin for Alcohol Use Disorders

NCT02046200

Phase 1/2 Completed 11 enrolled University of California, Los Angeles
RandomizedCrossoverTriple-blindTreatment

Summary

Current pharmacotherapies for alcohol use disorders (AUDs) have limited efficacy. Thus, the development of effective treatments for AUDs represents an important public health objective. Repositioning, i.e. using existing approved drugs for other indications, represents a fast and economically feasible approach for drug development. Ivermectin (IVM) is an FDA-approved antiparasitic medication that can significantly reduce alcohol intake in mice, suggesting that it may be useful in the treatment of AUDs in humans. The goal of this project is to provide key clinical evidence that IVM can be repositioned as a novel therapeutic agent to treat AUDs.

Timeline

Start
2014-02
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 30 mg Oral